Navigation Links
Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
Date:12/17/2013

Toronto, Canada (PRWEB) December 17, 2013

This webinar will discuss adaptive designs for phase I, phase II and phase III clinical trials in oncology and will take the form of a debate between two statisticians trying to meet the requirements of an oncologist. The panel will include Dr. Marc Buyse, Founder and Chairman of IDDI, Dr. Tomasz Burzykowski, Vice President of Research for IDDI, and Dr. Everardo Saad, Scientific Director and Chairman for Dendrix and Senior Oncology Consultant for IDDI.

The pros and cons of various adaptive designs will be discussed. Topics will include continual reassessment methods for phase I trials, adaptive Bayesian designs for phase III trials, adaptive sample size increases and adaptive enrichment of phase III trials.

For more information on this webinar or to register, visit: http://xtalks.com/Pros-and-Cons-of-Adaptive-Designs.ashx.

To learn more about IDDI, visit http://www.iddi.com.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 224
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11425544.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
2. Elsevier Introduces Adaptive Study Solution for Improved Learning and Memory Retention for Nursing and Health Professions
3. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
4. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
5. PI Releases High Power Piezo Amplifier to Drive Adaptive Structures, Fast Tool Servos, Vibration Cancellation Systems – Model E-482
6. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
7. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
8. “The New Health Conversation” to Premiere on PBS
9. GMO Answers Invites Consumers to Join the Online Conversation during GMO Awareness Month in October
10. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
11. Intrinsically disordered proteins: A conversation with Rohit Pappu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 ... ... Life -Sciences division, Treximo will pair its $200M operational capacity with its ... and project management in areas affecting quality and operational management. With ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
(Date:2/21/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Bioplastics & ... 12.8% over the next decade to reach approximately $8.9 billion by ... and forecasts for all the given segments on global as well ...
(Date:2/20/2017)... 2017 This report analyzes the worldwide markets for ... Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Read the full ... are provided for the period 2015 through 2022. Also, a ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):